Oscar Health, Inc. (OSCR)
Valuation Overview•Is Oscar Health, Inc. Overvalued or Undervalued?
Trading at a discount compared to peers, but the underlying intrinsic cash flows struggle to support the current price.
Fragile underlying quality score of 40/100; weak margins or elevated debt leverage warrant caution.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
OSCR struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($2.3B) and minimal debt risk.
The company is driving exceptional top-line expansion (41.6% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (0.1%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $4.6B | +27.5% | +41.6% | +81.8% | — | |
| EBITDA | $711.1M | — | +14.8% | — | — | |
| Net Income | $679.0M | -1842.5% | +9.9% | — | — | |
| EPS (Diluted) | $2.07 | -1865.9% | — | — | — | |
| Free Cash Flow | $2.6B | +11.4% | +44.4% | +38.4% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 17.4% | 18.4% | 51.1% | 65.0% |
| Operating Margin | 0.1% | -2.3% | -10.3% | -23.8% |
| Net Margin | -0.3% | -2.7% | -10.5% | -24.1% |
| FCF Margin | 21.0% | 4.8% | 2.4% | 1.8% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $1.21 | $2.07 | +71.1% | ||
| Q1'26 | $-0.92 | $-1.24 | -34.6% | ||
| Q4'25 | $-0.55 | $-0.53 | +3.6% | ||
| Q3'25 | $-0.90 | $-0.89 | +1.1% | ||
| Q2'25 | $0.83 | $0.92 | +10.8% | ||
| Q1'25 | $-0.55 | $-0.62 | -12.7% | ||
| Q4'24 | $-0.20 | $-0.22 | -10.0% | ||
| Q3'24 | $0.16 | $0.20 | +25.0% |
Total return is +51.3% (1Y), outperforming the benchmark by +26.3%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +89.7% | +80.4% | — |
| 1Y | +51.3% | +26.3% | — |
| 3YCAGR | +47.4% | +27.7% | — |
| 5YCAGR | +3.5% | -9.4% | — |
| 10YCAGR | -2.0% | -15.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Oscar Health, Inc. (OSCR) valuation, health, and returns.
Oscar Health, Inc. is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. overvalued (implying -50.0% downside from DCF intrinsic value of $14.21)
Oscar Health, Inc. has multiple valuation anchors: DCF Intrinsic Value: $14.21 | Peer Relative Fair Value: $79.95 | Wall Street Analyst Target: $24.20 (implying -14.8% upside). A convergence of these signals offers higher conviction.
Oscar Health, Inc. displays fair financial health with a composite quality score of 40/100, supported by a Piotroski F-Score of 4/9.
Oscar Health, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Oscar Health, Inc.'s current growth trajectory is Decelerating. The company achieved +27.5% 1Y revenue growth and -1865.9% 1Y EPS growth, compared to its 3Y revenue CAGR of +41.6%.
Wall Street consensus is Hold based on 11 analysts, beating EPS expectations in 75% of recent quarters with a 1-quarter streak. The consensus price target represents a -14.8% change from current levels.
Investment risks for Oscar Health, Inc. include: -51.7% 1-year max drawdown, high beta (1.71x market volatility). Volatility risk is characterized by a beta of 1.71x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.